دورية أكاديمية

Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?

التفاصيل البيبلوغرافية
العنوان: Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?
المؤلفون: Nickel, Miriam, Gissen, Paul, Greenaway, Rebecca, Cappelletti, Simona, Hamborg, Christiane, Ragni, Benedetta, Ribitzki, Tanja, Schulz, Angela, Tondo, Ilaria, Specchio, Nicola
المصدر: Neuropediatrics; Dec2023, Vol. 54 Issue 6, p402-406, 5p
مصطلحات موضوعية: LANGUAGE delay, NEURONAL ceroid-lipofuscinosis, ENZYME replacement therapy, EPILEPSY, CHILDREN'S language, SYMPTOMS
مستخلص: Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare pediatric disorder associated with rapid neurodegeneration, and premature death in adolescence. An effective enzyme replacement therapy (cerliponase alfa) has been approved that can reduce this predictable neurological decline. The nonspecific early symptoms of CLN2 disease frequently delay diagnosis and appropriate management. Seizures are generally recognized as the first presenting symptom of CLN2 disease, but emerging data show that language delay may precede this. An improved understanding of language deficits in the earliest stage of CLN2 disease may support the early identification of patients. In this article, CLN2 disease experts examine how language development is affected by CLN2 disease in their clinical practices. The authors' experiences highlighted the timings of first words and first use of sentences, and language stagnation as key features of language deficits in CLN2 disease, and how deficits in language may be an earlier sign of the disease than seizures. Potential challenges in identifying early language deficits include assessing patients with other complex needs, and recognizing that a child's language abilities are not within normal parameters given the variability of language development in young children. CLN2 disease should be considered in children presenting with language delay and/or seizures to facilitate earlier diagnosis and access to treatment that can significantly reduce morbidity. [ABSTRACT FROM AUTHOR]
Copyright of Neuropediatrics is the property of Georg Thieme Verlag Stuttgart and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:0174304X
DOI:10.1055/s-0043-1770143